13F Holdings
中文EN

NTRA Natera, Inc.

Services-Medical Laboratories · Nasdaq · SEC CIK 1604821 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY37.4%
TTM net income YoY46.7%
TTM EPS YoY51.1%
Revenue 3-yr CAGR43.3%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-9.0%
Net margin-5.7%
FCF margin1.8%
EBITDA margin-7.1%

Returns

ROE-10.6%
ROA-7.2%
ROIC (approx.)-41.9%
Asset turnover1.27x

Leverage & solvency

Liabilities / assets32.0%
Debt / equity0.00x
Current ratio2.81x
Interest coverage-70.84x

Cash quality & payout

Operating cash flow / net income-1.29x
Accruals ratio-16.5%
Payout ratio—
Capex / revenue5.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$2.31B$1.70B$1.08B$820.22M$625.49M
R&D expense$624.11M$404.14M$320.68M$316.42M$264.21M
SG&A expense$1.18B$841.31M$618.31M$588.59M$511.03M
Operating income-$309.91M-$222.29M-$446.25M-$541.04M-$468.17M
Interest expense$4.07M$10.69M$12.64M$9.32M$8.30M
Pretax income-$268.09M-$189.73M-$434.53M-$546.82M-$471.10M
Income tax-$59.93M$695,000$271,000$978,000$618,000
Net income-$208.16M-$190.43M-$434.80M-$547.80M-$471.72M
EBITDA-$268.15M-$191.33M-$422.15M-$524.34M-$456.92M
EPS (basic)-1.52-1.53-3.78-5.57-5.21
EPS (diluted)-1.52-1.53-3.78-5.57-5.21
Weighted avg. shares (diluted)136.72M124.72M115.00M98.41M90.56M
Banking
Provision for credit losses————$156,000
Balance sheet
Cash & equivalents$1.08B$945.59M$642.10M$466.09M$84.61M
Short-term investments—$22.69M$236.88M$432.30M$829.90M
Receivables$296.53M$314.17M$278.29M$244.38M$122.07M
Inventory$68.44M$44.74M$40.76M$35.41M$26.91M
Current assets$1.50B$1.38B$1.26B$1.21B$1.09B
PP&E, net$241.18M$162.05M$111.21M$92.45M$65.52M
Goodwill$141.07M————
Intangibles$373.71M$10.93M———
Total assets$2.40B$1.66B$1.44B$1.39B$1.24B
Current liabilities$441.23M$344.05M$307.27M$310.50M$218.96M
Short-term debt$80.32M$80.36M$80.40M$80.35M$50.05M
Long-term debt——$282.94M$281.65M$280.39M
Total debt——$363.35M$362.00M$330.45M
Total liabilities$685.93M$465.31M$676.37M$688.73M$583.18M
Shareholders' equity$1.71B$1.20B$765.33M$705.74M$653.30M
Net debt——-$278.75M-$104.09M$245.83M
Shares outstanding139.69M132.65M119.58M111.25M95.14M
Cash flow statement
Operating cash flow$215.30M$135.66M-$246.96M-$431.50M-$335.24M
Capital expenditure$106.19M$66.42M$39.20M$47.70M$41.03M
Free cash flow$109.11M$69.24M-$286.15M-$479.20M-$376.27M
Investing cash flow-$132.21M$137.62M$168.50M$330.34M-$205.19M
Financing cash flow$47.46M$30.20M$254.46M$482.64M$576.19M
Depreciation & amortization$41.76M$30.97M$24.10M$16.70M$11.25M
Stock-based compensation$354.40M$274.43M$191.81M$152.38M$115.22M

Free plan shows the latest 5 periods; Pro shows all 13 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.